Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
Democratic presidential candidate Hillary Clinton is the newest political figure urging Mylan to voluntarily lower the price of its life-saving EpiPen injection, reports Reuters.
When Ann Maxwell, assistant inspector general of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) testified before the Congressional Committee on Energy and Commerce's subcommittee on oversight and investigation in May of 2016, the new…
Rena Bielinski, Pharm.D., A.H.F.I.
Recall activity for pharmaceutical products rose 35 percent in the second quarter of 2016 to their highest level since the third quarter of 2014, according to a new Recall Index report. It also found that medical device recall activity increased…
Facing large scrutiny for the high price of its EpiPen medication, Mylan promised Thursday to lower the cost patients must pay for the life-saving injection, reported The Wall Street Journal.
Oak Brook, Ill.-based Medtronic acquired medical device manufacturer HeartWare International for $1.1 billion, according to Nasdaq.
The American Medical Association joined consumers and a handful of senators in scrutinizing Mylan's extreme price hikes for its life-saving EpiPen injection.
The Food and Drug Administration granted priority review status to Clovis Oncology's experimental cancer drug.
Starting September 24, the Food and Drug Administration will require all Class II devices to be labeled with unique device identifiers.
Manufacturers associated with the EpiPen device have drawn heavy criticism from consumers and lawmakers, but it's not the only lifesaving drug on the market experiencing soaring costs. Insulin prices have risen to nearly $400 a month in some cases, roughly…
Mylan's life-saving EpiPen injection device is not the only medication in the company's portfolio that has seen large price spikes, reports NBC News.